In this episode, we discuss the art of caring for terminally ill patients with Dr. Azra Raza. We also discuss her book titled "The First Cell", where she recounts numerous poignant stories of her patients with terminal cancer, and teaches us how to find hope amidst despair. Link to the book: https://www.amazon.com/First-Cell-Human-Pursuing-Cancer/dp/1541699521

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. Here are the shownotes:1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: https://x.com/Rfonsi1/status/1206004966294294528?s=20 2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:https://pubmed.ncbi.nlm.nih.gov/28655925/ 3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):https://pubmed.ncbi.nlm.nih.gov/33129376/ 4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:https://pubmed.ncbi.nlm.nih.gov/36779691/ 5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0 6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:https://pubmed.ncbi.nlm.nih.gov/34388020/ 7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:https://pubmed.ncbi.nlm.nih.gov/34470049/  

In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1  2. Elizabeth Schorb ASH 2022 (MARTA) 65-80 year olds – https://ashpublications.org/blood/article/140/Supplement%201/1773/493224/High-Dose-Chemotherapy-and-Autologous-Stem-Cell?searchresult=1  3. IESLG 32 study (MATRIX) - https://pubmed.ncbi.nlm.nih.gov/27132696/ and https://pubmed.ncbi.nlm.nih.gov/35562406/  4. R-methotrexate procarbazine (PRIMAIN) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/  5. RW studies: Andy Evens 500 pts >60 - https://pubmed.ncbi.nlm.nih.gov/36965007/  6. LYSA PRECIS study https://pubmed.ncbi.nlm.nih.gov/35834762/  7. IELSG43 study Lugano (https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3163_15)  and ASH late breaking 2022 (https://ashpublications.org/blood/article/140/Supplement%202/LBA-3/493427/Effects-on-Survival-of-Non-Myeloablative)  8. Secondary CNS lymphoma 134 pts UK PR vs CR autograft - https://pubmed.ncbi.nlm.nih.gov/36300776/  9. “How I Treat secondary CNS involvement by aggressive lymphomas?”-     https://pubmed.ncbi.nlm.nih.gov/37702537/   

The podcast discusses the management of high-risk myeloma, including genetic markers and prognostic factors. It explores the impact of Dell 1P32 and other chromosome 1 nuances on newly diagnosed myeloma. Treatment options and the role of autologous transplant are also discussed. Implementation of gene expression profiling and genetic profiling in managing high-risk myeloma is highlighted. The challenges of using synthetic control arms in clinical trials and the management of high-risk myeloma are explored.

In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed: 1. “How I Treat Peripheral T-cell Lymphoma?”:https://pubmed.ncbi.nlm.nih.gov/24615779/2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:https://pubmed.ncbi.nlm.nih.gov/34921960/3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:https://pubmed.ncbi.nlm.nih.gov/34843406/4. RCT of autologous vs allogeneic HSCT as part of 1st line therapy in poor risk peripheral T-cell lymphoma:https://pubmed.ncbi.nlm.nih.gov/33512419/5. A phase 2 biomarker-driven study of ruxolitinib in T-cell lymphomas:https://pubmed.ncbi.nlm.nih.gov/34653242/6. JACKPOT8 study: Selective JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma:https://ash.confex.com/ash/2020/webprogram/Paper134650.html

In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes:1. CCUS and risk of transformation to myeloid neoplasms:https://www.sciencedirect.com/science/article/pii/S0006497121013471 2. Prediction of risk for myeloid neoplasms in clonal hematopoiesis:https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200310 3. CHRS risk score:http://www.chrsapp.com 4. Germline predisposition to clonal hematopoiesis: https://www.sciencedirect.com/science/article/abs/pii/S0145212623006094?via%3Dihubhttps://www.nature.com/articles/s41586-020-2819-2 5. Cancer therapy shapes the fitness landscape of clonal hematopoiesis:https://www.nature.com/articles/s41588-020-00710-0 6. Canakinumab for the prevention of progression to cancer in patients with Clonal Cytopenias of Unknown Significance, IMPACT Study:https://clinicaltrials.gov/study/NCT05641831?cond=CCUS%20Clonal%20Cytopenia%20of%20Undetermined%20Significance&rank=3 7. Ivosidenib in patients with CCUS and mutations in IDH1:https://classic.clinicaltrials.gov/ct2/show/NCT05030441https://sites.wustl.edu/pimm/

In this episode, we delve into the diagnosis and management of Paroxysmal Nocturnal Hemoglobinuria (PNH) with Dr. Robert Brodsky. Here are the shownotes for key papers we discussed in the episode:How I treat PNH: https://pubmed.ncbi.nlm.nih.gov/33512400/Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia: https://pubmed.ncbi.nlm.nih.gov/37084383/Pegcetacoplan versus eculizumab in PNH: a) https://pubmed.ncbi.nlm.nih.gov/33730455/  b) https://pubmed.ncbi.nlm.nih.gov/35349667/Phase 2 study of danicopan (factor d inhibitor) in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab: https://pubmed.ncbi.nlm.nih.gov/34314483/Complement and prothrombotic state: https://pubmed.ncbi.nlm.nih.gov/34415298/

In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University.Link for our Blood Cancer Talks Survey: https://bit.ly/BCTSHere are the key trials we discussed:1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/27332902/ 2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/27069074/ 3. ECHELON-1 (Replacing Bleomycin by Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/29224502/https://pubmed.ncbi.nlm.nih.gov/35830649/ 4. BREACH (BV-AVD vs ABVD for Early Stage Unfavorable Hodgkin’s Lymphoma):https://pubmed.ncbi.nlm.nih.gov/35867960/ 5. S1826 (Nivo-AVD vs BV-AVD in Advanced Hodgkin’s Lymphoma):https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA4 6. FIL-ROUGE (PET-adapted ABVD vs Dose-Intensified ABVD):https://onlinelibrary.wiley.com/doi/10.1002/hon.3163_4 7.  HD21 (BRECADD vs EBEACOPP in Advanced Hodgkin’s Lymphoma):https://onlinelibrary.wiley.com/doi/10.1002/hon.3196_LBA5

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.Here are some of the key articles we discussed:1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.      https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score:     https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”.     https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):    https://pubmed.ncbi.nlm.nih.gov/36906275/ 5. ASTCT consensus grading for CRS and ICANS:    https://pubmed.ncbi.nlm.nih.gov/30592986/6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:    https://pubmed.ncbi.nlm.nih.gov/35696759/ 7. Modified EASIX score for predicting CRS and neurotoxicity:    https://pubmed.ncbi.nlm.nih.gov/34432870/

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf92. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:a) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/b) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma: https://pubmed.ncbi.nlm.nih.gov/36690811/4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma: https://pubmed.ncbi.nlm.nih.gov/36413381/